Halberd Corporation Research on Covid-19 Treatment Development Begins at ASU
Halberd Corporation announced the commencement of research at Arizona State University (ASU) aimed at developing antibodies related to COVID-19. This research supports two issued patents and three provisional patent applications focusing on the extracorporeal removal of the virus' antigens from blood. The CEO expressed confidence in ASU's capabilities, particularly in the initial research phase. Halberd holds exclusive rights to various COVID-19 treatment patents, enhancing its position in the healthcare space amid the pandemic.
- Research collaboration with Arizona State University to develop COVID-19 treatment.
- Holds exclusive rights to multiple COVID-19 related patents.
- Forward-looking statements carry risks and uncertainties regarding actual results.
- Impact of COVID-19 on operations remains unknown, raising investor caution.
Halberd Corporation Research on Covid-19 Treatment Development Begins at ASU
JACKSON CENTER, PA / ACCESSWIRE / September 8, 2020 / Halberd Corporation (OTC PINK:HALB) today announced Arizona State University (ASU) commenced its research work for Halberd Corp. The initial phases of ASU's research focuses on the development of antibodies in support of Halberd's two issued patents and three Covid-19 related provisional patent applications for extracorporeal removal of the virus' antigens from a patient's blood. Those antibodies could be multifaceted, including with regard to other viruses. The research will also focus on neutralizing the effects of antigens and developing one or more therapies.
William A. Hartman, Chairman, President and CEO of Halberd Corporation stated, "ASU has assembled an excellent team of very impressive scientists and researchers. We have every confidence they can deliver the desired results. We are particularly impressed with their focus on Phase 1 of the research."
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133
Twitter:@HalberdC
About Arizona State University.
Arizona State University is a public research university with 5 campuses in and around Phoenix, with four regional centers throughout Arizona. It is one of the largest public universities, based on enrollment, and one of the fastest growing research universities in the United States. The school boasts over 400 National Academies-honored faculty, and 77 elite programs.
About Halberd Corporation.
HalberdCorporation. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" and "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Title | Application No. | Filing Date | Priority | Status |
Method for Treating and Curing Covid-19 Infection | US 62/989981 | 03/16/2020 | n/a | Provisional application Pending |
Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients | US 63/007207 | 04/08/2020 | n/a | Provisional application Pending |
Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus | US 63/013104 | 4/21/2020 | n/a | Provisional application Pending |
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
SOURCE: Halberd Corporation
View source version on accesswire.com:
https://www.accesswire.com/605073/Halberd-Corporation-Research-on-Covid-19-Treatment-Development-Begins-at-ASU
FAQ
What is the latest update on Halberd Corporation's research for COVID-19?
How many patents does Halberd Corporation hold for COVID-19 treatments?
What is Halberd Corporation's stock symbol?
What are the risks mentioned by Halberd Corporation regarding their COVID-19 initiatives?
Who expressed confidence in the ASU research team for Halberd Corporation?
